A biosensor of S100A4 metastasis factor activation: Inhibitor screening and cellular activation dynamics

Sarah C. Garrett, Louis Hodgson, Andrew Rybin, Alexei Toutchkine, Klaus M. Hahn, David S. Lawrence, Anne R. Bresnick

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

S100A4, a member of the S100 family of Ca2+-binding proteins, displays elevated expression in malignant human tumors compared with benign tumors, and increased expression correlates strongly with poor patient survival. S100A4 has a direct role in metastatic progression, likely due to the modulation of actomyosin cytoskeletal dynamics, which results in increased cellular motility. We developed a fluorescent biosensor (Mero-S100A4) that reports on the Ca2+-bound, activated form of S100A4. Direct attachment of a novel solvatochromatic reporter dye to S100A4 results in a sensor that, upon activation, undergoes a 3-fold enhancement in fluorescence, thus providing a sensitive assay for use in vitro and in vivo. In cells, localized activation of S100A4 at the cell periphery is observed during random migration and following stimulation with lysophosphatidic acid, a known activator of cell motility and proliferation. Additionally, a screen against a library of FDA-approved drugs with the biosensor identified an array of phenothiazines as inhibitors of myosin-II associated S100A4 function. These data demonstrate the utility of the new biosensor both for drug discovery and for probing the cellular dynamics controlled by the S100A4 metastasis factor.

Original languageEnglish (US)
Pages (from-to)986-996
Number of pages11
JournalBiochemistry
Volume47
Issue number3
DOIs
StatePublished - Jan 22 2008

Fingerprint

Biosensing Techniques
Biosensors
Screening
Chemical activation
Neoplasm Metastasis
Tumors
Myosin Type II
Phenothiazines
Actomyosin
Drug Discovery
Cell Movement
Assays
Neoplasms
Carrier Proteins
Coloring Agents
Fluorescence
Display devices
Cell Proliferation
Modulation
Survival

ASJC Scopus subject areas

  • Biochemistry

Cite this

A biosensor of S100A4 metastasis factor activation : Inhibitor screening and cellular activation dynamics. / Garrett, Sarah C.; Hodgson, Louis; Rybin, Andrew; Toutchkine, Alexei; Hahn, Klaus M.; Lawrence, David S.; Bresnick, Anne R.

In: Biochemistry, Vol. 47, No. 3, 22.01.2008, p. 986-996.

Research output: Contribution to journalArticle

Garrett, Sarah C. ; Hodgson, Louis ; Rybin, Andrew ; Toutchkine, Alexei ; Hahn, Klaus M. ; Lawrence, David S. ; Bresnick, Anne R. / A biosensor of S100A4 metastasis factor activation : Inhibitor screening and cellular activation dynamics. In: Biochemistry. 2008 ; Vol. 47, No. 3. pp. 986-996.
@article{6b9d07ec5c604aa28efc167648b51260,
title = "A biosensor of S100A4 metastasis factor activation: Inhibitor screening and cellular activation dynamics",
abstract = "S100A4, a member of the S100 family of Ca2+-binding proteins, displays elevated expression in malignant human tumors compared with benign tumors, and increased expression correlates strongly with poor patient survival. S100A4 has a direct role in metastatic progression, likely due to the modulation of actomyosin cytoskeletal dynamics, which results in increased cellular motility. We developed a fluorescent biosensor (Mero-S100A4) that reports on the Ca2+-bound, activated form of S100A4. Direct attachment of a novel solvatochromatic reporter dye to S100A4 results in a sensor that, upon activation, undergoes a 3-fold enhancement in fluorescence, thus providing a sensitive assay for use in vitro and in vivo. In cells, localized activation of S100A4 at the cell periphery is observed during random migration and following stimulation with lysophosphatidic acid, a known activator of cell motility and proliferation. Additionally, a screen against a library of FDA-approved drugs with the biosensor identified an array of phenothiazines as inhibitors of myosin-II associated S100A4 function. These data demonstrate the utility of the new biosensor both for drug discovery and for probing the cellular dynamics controlled by the S100A4 metastasis factor.",
author = "Garrett, {Sarah C.} and Louis Hodgson and Andrew Rybin and Alexei Toutchkine and Hahn, {Klaus M.} and Lawrence, {David S.} and Bresnick, {Anne R.}",
year = "2008",
month = "1",
day = "22",
doi = "10.1021/bi7021624",
language = "English (US)",
volume = "47",
pages = "986--996",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - A biosensor of S100A4 metastasis factor activation

T2 - Inhibitor screening and cellular activation dynamics

AU - Garrett, Sarah C.

AU - Hodgson, Louis

AU - Rybin, Andrew

AU - Toutchkine, Alexei

AU - Hahn, Klaus M.

AU - Lawrence, David S.

AU - Bresnick, Anne R.

PY - 2008/1/22

Y1 - 2008/1/22

N2 - S100A4, a member of the S100 family of Ca2+-binding proteins, displays elevated expression in malignant human tumors compared with benign tumors, and increased expression correlates strongly with poor patient survival. S100A4 has a direct role in metastatic progression, likely due to the modulation of actomyosin cytoskeletal dynamics, which results in increased cellular motility. We developed a fluorescent biosensor (Mero-S100A4) that reports on the Ca2+-bound, activated form of S100A4. Direct attachment of a novel solvatochromatic reporter dye to S100A4 results in a sensor that, upon activation, undergoes a 3-fold enhancement in fluorescence, thus providing a sensitive assay for use in vitro and in vivo. In cells, localized activation of S100A4 at the cell periphery is observed during random migration and following stimulation with lysophosphatidic acid, a known activator of cell motility and proliferation. Additionally, a screen against a library of FDA-approved drugs with the biosensor identified an array of phenothiazines as inhibitors of myosin-II associated S100A4 function. These data demonstrate the utility of the new biosensor both for drug discovery and for probing the cellular dynamics controlled by the S100A4 metastasis factor.

AB - S100A4, a member of the S100 family of Ca2+-binding proteins, displays elevated expression in malignant human tumors compared with benign tumors, and increased expression correlates strongly with poor patient survival. S100A4 has a direct role in metastatic progression, likely due to the modulation of actomyosin cytoskeletal dynamics, which results in increased cellular motility. We developed a fluorescent biosensor (Mero-S100A4) that reports on the Ca2+-bound, activated form of S100A4. Direct attachment of a novel solvatochromatic reporter dye to S100A4 results in a sensor that, upon activation, undergoes a 3-fold enhancement in fluorescence, thus providing a sensitive assay for use in vitro and in vivo. In cells, localized activation of S100A4 at the cell periphery is observed during random migration and following stimulation with lysophosphatidic acid, a known activator of cell motility and proliferation. Additionally, a screen against a library of FDA-approved drugs with the biosensor identified an array of phenothiazines as inhibitors of myosin-II associated S100A4 function. These data demonstrate the utility of the new biosensor both for drug discovery and for probing the cellular dynamics controlled by the S100A4 metastasis factor.

UR - http://www.scopus.com/inward/record.url?scp=38349151537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349151537&partnerID=8YFLogxK

U2 - 10.1021/bi7021624

DO - 10.1021/bi7021624

M3 - Article

C2 - 18154362

AN - SCOPUS:38349151537

VL - 47

SP - 986

EP - 996

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 3

ER -